Translational neuroimmunology in multiple sclerosis : from disease mechanisms to clinical applications /: from disease mechanisms to clinical applications. (2016)

• Record Type: Book
• Further Information: Note: Ruth Arnon, Ariel Miller.
• Authors: Arnon, R; Miller, Ariel
• Contents: Section I: MS Pathology and Mechanisms 1. MS Pathology: Inflammation versus Neurodegeneration 2. Immune Dysregulation in Multiple Sclerosis 3. CNS immune regulation 4. Genetics of Multiple Sclerosis 5. MS Subtypes: How the Natural History of MS was Challenged Due to Treatment 6. Pediatric-Onset MS as a Window into Early Disease Targets and Mechanisms 7. Sex-related factors in multiple sclerosis Section II: Other Patho-Mechanisms 8. Environmental Factors and their regulation of immunity in MS 9. Gut Microbiota in Multiple Sclerosis: A Bioreactor driving Brain Autoimmunity 10. Glutamate and Multiple Sclerosis: glutamate receptors and effects in the CNS, glutamate receptors and direct effects on T cells, and contribution of both to Multiple Sclerosis 11. Dopamine, T cells and Multiple Sclerosis: Dopamine receptors and direct effects on T cells, dopamine production in T cells, abnormalities in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis, and their correction by treatment 12. Neuroendocrine Checkpoints of Innate Immune Responses in Multiple Sclerosis: Reciprocal Interactions between Body and Brain 13. Fighting chronic neuroinflammation by boosting autoimmunity: the distinction between neurodegenerative diseases and multiple sclerosis 14. Neuroactive steroids and Neuroinflammation Section III: Surrogate Markers in Multiple Sclerosis 15. Surrogate Markers in Multiple Sclerosis: The Role of MRI Section IV: Currently Approved Therapies – Injectable 16. Interferon ß in Multiple Sclerosis: A Review 17. Glatiramer Acetate - From Bench to Bed and Back 18. Natalizumab 19. Alemtuzumab (Campath-1H) 20. Currently approved DMDs-injectable: cytotoxic immunosuppressive drugs Section V: Currently Approved DMDs – Oral 21. Fingolimod (Gilenya) 22. Oral Dimethyl Fumarate (BG-12; Tecfidera®) for Multiple Sclerosis 23. Emerging MS Therapies in the Horizon Section VI: Symptomatic and Complementary Treatments 24. Treatment of acute relapses in Multiple sclerosis 25. Shedding light on Vitamin D and MS 26. Symptomatic and Complementary Treatments 27. Cognitive Impairment in Multiple Sclerosis Section VII. Novel & Emerging Strategies 28. Personalized Medicine and Theranostics: Applications to Multiple Sclerosis 29. Stem cell based-therapies, remyelination and repair promotion, in the treatment of multiple sclerosis 30. Stem cells in Multiple Sclerosis 31. T cell vaccination: An insight into T cell regulation 32. Reversal of Misfortune: Therapeutic Strategies on the Horizon
• Publisher Details: Amsterdam : Academic Press
• Publication Date: 2016
• Extent: 1 online resource
• Subjects: 616.834; Multiple sclerosis -- Immunological aspects; Multiple sclerosis -- Treatment
• Languages: English
• ISBNs: 9780128020074
• Related ISBNs: 9780128019146
• Notes: Note: Description based on CIP data; item not viewed.
• Access Rights: Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
• Access Usage: Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.